醋托芬与可乐定治疗阿片类药物戒断症状的比较。

Comparison of acetorphan with clonidine for opiate withdrawal symptoms.

作者信息

Hartmann F, Poirier M F, Bourdel M C, Loo H, Lecomte J M, Schwartz J C

机构信息

Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Centre Hospitalier Sainte-Anne, Paris, France.

出版信息

Am J Psychiatry. 1991 May;148(5):627-9. doi: 10.1176/ajp.148.5.627.

DOI:10.1176/ajp.148.5.627

PMID:2018165

Abstract

OBJECTIVE AND METHOD

The authors compared the effects of acetorphan, an enkephalinase inhibitor, with those of clonidine for the treatment of the opioid withdrawal syndrome. Nineteen patients addicted to heroin or synthetic opiates who were undergoing drug withdrawal and displayed a withdrawal syndrome according to DSM-III criteria were studied for 5 days in a hospital setting. In a double-blind trial, 10 subjects were given acetorphan intravenously and nine were given clonidine; objective signs and subjective symptoms of withdrawal were recorded.

RESULTS

On several objective signs, the effect of acetorphan was more marked than that of clonidine, whereas the two drugs exhibited similar efficacy with respect to the subjective components of withdrawal. No side effect was noted in the subjects who received acetorphan.

CONCLUSIONS

Enkephalinase inhibition may constitute a novel and safe therapeutic approach to the opioid withdrawal syndrome.

摘要

目的与方法

作者比较了脑啡肽酶抑制剂醋托芬与可乐定治疗阿片类戒断综合征的效果。19名对海洛因或合成阿片类药物成瘾且正在戒毒、根据《精神疾病诊断与统计手册》第三版标准表现出戒断综合征的患者在医院环境中接受了5天的研究。在一项双盲试验中，10名受试者静脉注射醋托芬，9名受试者注射可乐定；记录戒断的客观体征和主观症状。